Email This Release
Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3
*
marks required fields
Recipient Name:
*
Recipient Email:
Message:
*
Enter security words: